Lupin's SOLOSEC gets prefered status in US formulary
Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among women of childbearing age.;
Baltimore: Lupin Pharmaceuticals Inc., the U.S. based wholly-owned subsidiary of Lupin Limited, has announced that Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women has received preferred coverage effective immediately on the Express Scripts National Preferred, Flex, and Basic commercial formularies. As a preferred medication, Solosec® will be available at a lower out-of-pocket cost to the represented Express Scripts plan members compared to BV medications which are non-preferred or excluded.
Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among women of childbearing age. This next-generation treatment is designed to deliver a full course of therapy in just one packet.
"As one of the largest pharmacy benefit managers in the U.S., Express Scripts' decision to include Solosec® as a preferred agent on its national formularies is a significant step toward ensuring access to it for BV patients," said Ms Vinita Gupta, CEO of Lupin Limited. "We believe our pricing and access strategy prioritizes patients by providing a novel, first-of-its-kind BV treatment at pricing designed to reduce barriers to treatment with Solosec®."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.